Last reviewed · How we verify
TNP-2198
At a glance
| Generic name | TNP-2198 |
|---|---|
| Also known as | Rifasutenizol |
| Sponsor | TenNor Therapeutics (Suzhou) Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection (PHASE3)
- Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin (PHASE1)
- Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants (PHASE2)
- A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules (PHASE1, PHASE2)
- Human Mass Balance and Biotransformation Study of [14C]TNP-2198 (PHASE1)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNP-2198 CI brief — competitive landscape report
- TNP-2198 updates RSS · CI watch RSS
- TenNor Therapeutics (Suzhou) Limited portfolio CI